Related Experiment Videos
Endometrial effect of transdermal estradiol and progestin ST-1435 in postmenopausal women
S Suhonen1, M Haukkamaa, P Lähteenmäki
1Department of Obstetrics and Gynecology, City Maternity Hospital, Helsinki, Finland.
Objective:
To study the endometrial effect of the transdermal synthetic progestin ST-1435.
Design:
Prospective.
Setting:
City Maternity Hospital, Helsinki, Finland.
Patients:
Eleven postmenopausal women used transdermal estradiol (E2) patches for 6 weeks immediately before a vaginal operation for prolapse. For the last 10 days, 1 mg of ST-1435 transdermally in a gel was combined to the treatment.
Main Outcome Measures:
Blood samples were taken to follow serum concentrations of E2, follicle-stimulating hormone, and ST-1435. Endometrial samples for histologic examination were collected during the operation to evaluate the effect of the progestin.
Results:
Transdermal absorption of ST-1435 resulted in reasonably constant serum concentrations of ST-1435 in each subject. A progestin effect on the endometrium was seen in 9 of 10 samples obtained. One sample did not show any progestin effect in spite of adequate ST-1435 levels, but this patient's E2 concentrations were low.
Conclusions:
When the estrogen stimulation was adequate, the transdermal ST-1435 induced a progestin effect on the endometrium, i.e., it had an end-organ effect.